Primary Biliary Cholangitis

Primary Biliary Cholangitis (PBC) is a chronic, progressive autoimmune liver disease characterized by immune-mediated destruction of intrahepatic bile ducts, leading to cholestasis, fibrosis, and eventually cirrhosis if untreated. This presentation explores the epidemiology, etiology, and clinical features of PBC, highlighting its prevalence among women aged 40–60 with strong genetic and autoimmune associations. Key sections cover risk factors such as female gender, environmental triggers, and coexisting autoimmune conditions like Sjögren’s syndrome. Common symptoms include fatigue, pruritus, and jaundice, while diagnosis relies on anti-mitochondrial antibody (AMA) detection, liver enzyme testing, and biopsy. Conventional treatments such as ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are discussed alongside emerging therapies targeting immune regulation and liver regeneration. The presentation also introduces holistic regenerative approaches, including stem cell and immunomodulatory therapies, emphasizing precision medicine and early intervention to improve long-term outcomes and quality of life for PBC patients.